



**SZABO
SCANDIC**

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic



PRODUCT INFORMATION



Rasagiline-¹³C₃ (mesylate)

Item No. 31688

CAS Registry No.: 1391052-18-8

Formal Name: (R)-N-(prop-2-yn-1-yl-¹³C₃)-2,3-dihydro-1H-inden-1-amine, monomethanesulfonate

MF: C₉[¹³C]₃H₁₃N • CH₃SO₃H


FW: 270.3

Purity: ≥95%

Supplied as: A solid

Storage: -20°C

Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Rasagiline-¹³C₃ (mesylate) is supplied as a solid. A stock solution may be made by dissolving the rasagiline-¹³C₃ (mesylate) in the solvent of choice, which should be purged with an inert gas. Rasagiline-¹³C₃ (mesylate) is slightly soluble in DMSO and methanol.

Description

Rasagiline-¹³C₃ is intended for use as an internal standard for the quantification of rasagiline (Item No. 14917) by GC- or LC-MS. Rasagiline is an inhibitor of monoamine oxidase B (MAO-B; IC₅₀ = 4.43 nM for the rat brain enzyme).¹ It is selective for MAO-B over MAO-A (IC₅₀ = 412 nM for the rat brain enzyme). It inhibits serum and NGF withdrawal-induced apoptosis of PC12 cells when used at concentrations ranging from 0.01 to 100 μM.² Rasagiline inhibits rat brain MAO-B *in vivo* (ED₅₀ = 0.1 mg/kg).¹ It reduces cerebral edema in a mouse model of traumatic brain injury.² Rasagiline (0.1 mg/kg) reduces cortical and hippocampal levels of full-length and soluble amyloid precursor protein (APP) in rats and mice. It also reduces α-synuclein-induced substantia nigra neuron loss and improves motor dysfunction in a mouse model of Parkinson's disease.³ Formulations containing rasagiline have been used in the treatment of Parkinson's disease.

References

1. Youdim, M.B.H., Gross, A. and Finberg, J.P. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. *Brit. J. Pharmacol.* **132**(2), 500-506 (2001).
2. Youdim, M.B.H. and Weinstock, M. Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R) aminoindan-5-YL)-ethyl methyl carbamate]. *Cell. Mol. Neurobiol.* **21**(6), 555-573 (2001).
3. Kang, S.S., Ahn, E.H., Zhang, Z., et al. α-Synuclein stimulation of monoamine oxidase-B and legumain protease mediates the pathology of Parkinson's disease. *EMBO J.* **37**(12), e98878 (2018).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 - USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM